Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 9 de 9
Filtrer
Plus de filtres











Gamme d'année
1.
Clin Oral Investig ; 25(6): 3739-3745, 2021 Jun.
Article de Anglais | MEDLINE | ID: mdl-33387032

RÉSUMÉ

OBJECTIVE: To assess whether the administration of meloxicam before head and neck radiotherapy reduces the risk of mandibular osteoradionecrosis in rats. MATERIAL AND METHODS: Sixty male Wistar rats were randomly divided into 6 groups (n = 10) according to the meloxicam administration and radiation therapy: control (C), irradiated (I), single dose of meloxicam (M1), single dose of meloxicam and irradiated (M1I), triple dose of meloxicam (M3), triple dose of meloxicam and irradiated (M3I). Meloxicam was administrated (20 mg/kg per dose) 1 h before the radiation therapy (single dose of 20 Gy) and 24 h and 48 h after the radiation therapy for groups with two additional doses. Ten days after the radiation therapy, the three right mandibular molars were extracted from all rats, who were euthanatized after 21 or 35 days (n = 5 per group). The mandibles were assessed by macroscopic evaluation and micro-CT analysis. RESULTS: The right hemimandibles of the irradiated groups revealed macroscopic signs of osteoradionecrosis, and those of the non-irradiated groups revealed complete gingival healing. A significant delay in alveolar socket healing in all irradiated groups was observed in the micro-CT assessment regardless meloxicam treatment. CONCLUSION: The administration of meloxicam before head and neck radiotherapy does not reduce the risk of mandibular osteoradionecrosis when associated to dental extractions. CLINICAL RELEVANCE: Since meloxicam has been shown to be a potential radiation-protective agent, and osteoradionecrosis physiopathology is believed to be related to an inflammatory process, possible interactions are relevant to be investigated.


Sujet(s)
Tumeurs de la tête et du cou , Maladies mandibulaires , Ostéoradionécrose , Animaux , Mâle , Mandibule , Maladies mandibulaires/étiologie , Maladies mandibulaires/prévention et contrôle , Méloxicam , Ostéoradionécrose/prévention et contrôle , Rats , Rat Wistar , Microtomographie aux rayons X
2.
Int J Radiat Biol ; 93(2): 204-213, 2017 02.
Article de Anglais | MEDLINE | ID: mdl-27600691

RÉSUMÉ

PURPOSE: Whole brain irradiation (WBI) causes a variety of secondary side-effects including anorexia and bone necrosis. We evaluated the radiomodifying effect of black grape juice (BGJ) on WBI alterations in rats measuring food and water intake, body weight, hemogram, and morphological and histological mandibular parameters. MATERIALS AND METHODS: Forty male rats (200-250 g) were exposed to eight sessions of cranial X-ray irradiation. The total dose absorbed was 32 Gy delivered over 2 weeks. Four groups were defined: (i) NG: non-irradiated, glucose and fructose solution-supplemented (GFS); (ii) NJ: non-irradiated, BGJ-supplemented; (iii) RG: irradiated, GFS-supplemented; and (iv) RJ: irradiated, BGJ-supplemented. Rats received daily BGJ or GFS dosing by gavage starting 4 days before, continuing during, and ending 4 days after WBI. RESULTS: RJ rats ingested more food and water and showed less body weight loss than RG rats during the irradiation period. Forty days after WBI, irradiated animals started losing weight again compared with controls as a consequence of masticatory hypofunction by mandibular osteoradionecrosis (ORN). Osteoclastic activity and inflammation were apparent in RG rat mandibles. BGJ was able to attenuate the severity of ORN as well as to improve white and red blood cell counts. CONCLUSIONS: Fractionated whole brain irradiation induces mandibular changes that interfere with normal feeding. BGJ can be used to mitigate systemic side-effects of brain irradiation and ORN.


Sujet(s)
Irradiation crânienne/effets indésirables , Maladies mandibulaires/prévention et contrôle , Maladies mandibulaires/physiopathologie , Ostéoradionécrose/prévention et contrôle , Ostéoradionécrose/physiopathologie , Radioprotecteurs/administration et posologie , Vitis/composition chimique , Animaux , Jus de fruits et de légumes , Mâle , Maladies mandibulaires/étiologie , Ostéoradionécrose/étiologie , Rats , Rat Wistar , Résultat thérapeutique
3.
Clin Oral Implants Res ; 26(1): 102-8, 2015.
Article de Anglais | MEDLINE | ID: mdl-24313325

RÉSUMÉ

OBJECTIVE: To compare with pristine sites bone resorption and soft tissue adaptation at implants placed immediately into extraction sockets (IPIES) in conjunction with deproteinized bovine bone mineral (DBBM) particles and a collagen membrane. MATERIAL AND METHODS: The mesial root of the third premolar in the left side of the mandible was endodontically treated (Test). Flaps were elevated, the tooth hemi-sectioned, and the distal root removed to allow the immediate installation of an implant into the extraction socket in a lingual position. DBBM particles were placed into the defect and on the outer contour of the buccal bony ridge, concomitantly with the placement of a collagen membrane. A non-submerged healing was allowed. The premolar on the right side of the mandible was left in situ (control). Ground sections from the center of the implant as well as from the center of the distal root of the third premolar of the opposite side of the mandible were obtained. The histological image from the implant site was superimposed to that of the contralateral pristine distal alveolus, and dimensional variation evaluated for the hard tissue and the alveolar ridge. RESULTS: After 3 months of healing, both histological and photographic evaluation revealed a reduction of hard and soft tissue dimensions. CONCLUSION: The contour augmentation performed with DBBM particles and a collagen membrane at the buccal aspects of implants placed IPIES was not able to maintain the tissue volume.


Sujet(s)
Résorption alvéolaire/prévention et contrôle , Substituts osseux/pharmacologie , Collagène/pharmacologie , Pose immédiate d'implant dentaire/méthodes , Maladies mandibulaires/prévention et contrôle , Membrane artificielle , Animaux , Prémolaire , Chiens , Photographie (méthode) , Extraction dentaire , Alvéole dentaire/chirurgie
4.
J Periodontal Res ; 49(6): 729-35, 2014 Dec.
Article de Anglais | MEDLINE | ID: mdl-24372313

RÉSUMÉ

BACKGROUND AND OBJECTIVE: After activation, platelets express mediators that modulate inflammation. We hypothesized that drug-induced platelet inactivation may interfere in the inflammatory process in experimental periodontal disease by suppressing the release of biological mediators to the injury site. MATERIAL AND METHODS: To evaluate the effects of antiplatelet drugs on experimental periodontal disease, 60 rats were randomly assigned to six groups (n = 10) and ligatures were placed around lower first molars in three groups. The other three groups were not subjected to the induction of periodontal disease and were used as negative controls. During the experimental period, animals were given aspirin (30 mg/kg) or clopidogrel (75 mg/kg) intragastrically once daily for 3 d. On day 3, they were killed and gingival tissue were used to evaluate myeloperoxidase activity and the expression of the chemokine CXCL4. Hemi-mandibles were used for microscopic evaluation. RESULTS: Clopidogrel significantly reduced the inflammatory infiltrate and increased the amount of collagen fibers. Histometric analysis showed that clopidogrel impaired alveolar bone loss. Expression of CXCL4 was significantly increased (p < 0.001) in rats subjected to periodontal disease. Systemic administration of aspirin and clopidogrel induced a significant decrease ( p < 0.05) in the expression of CXCL4. Treatment with antiplatelet drugs resulted in a significant reduction of myeloperoxidase activity when compared to saline-treated animals with periodontal disease. CONCLUSION: Clopidogrel but not aspirin showed the ability of preventing bone loss in experimental periodontitis.


Sujet(s)
Anti-inflammatoires/usage thérapeutique , Parodontite/traitement médicamenteux , Antiagrégants plaquettaires/usage thérapeutique , Résorption alvéolaire/prévention et contrôle , Animaux , Acide acétylsalicylique/usage thérapeutique , Clopidogrel , Collagène/effets des médicaments et des substances chimiques , Tissu conjonctif/effets des médicaments et des substances chimiques , Tissu conjonctif/anatomopathologie , Modèles animaux de maladie humaine , Gencive/effets des médicaments et des substances chimiques , Gencive/anatomopathologie , Médiateurs de l'inflammation/antagonistes et inhibiteurs , Mâle , Maladies mandibulaires/prévention et contrôle , Parodontite/immunologie , Parodontite/anatomopathologie , Myeloperoxidase/analyse , Facteur-4 plaquettaire/analyse , Répartition aléatoire , Rats , Rat Sprague-Dawley , Ticlopidine/analogues et dérivés , Ticlopidine/usage thérapeutique
5.
Clin Oral Investig ; 15(6): 967-73, 2011 Dec.
Article de Anglais | MEDLINE | ID: mdl-20820824

RÉSUMÉ

Previous reports have demonstrated increased tryptase-like proteolytic activity in the crevicular fluid of patients with periodontal disease. In the present study, we have investigated the effect of tryptase inhibition with nafamostat mesilate (NM, 6-amino-2-naphtlyl p-guanidinobenzoate dimethansulfonate) on the development of experimental periodontitis in rats. Eighty (80) male Wistar rats were randomly separated into four groups: Control group, NM group (daily 0.1 mg/kg body weight of NM, i.p.), Ligature group (ligature placed at lower right first molars), and NM+Ligature group. The amount of alveolar bone loss (ABL) around the mesial root surface of the first mandibulary molar, as well as the myeloperoxidase (MPO) activity, and total proteolytic activity [N-benzoyl-L: -arginine-p-nitroanilide (BApNA) substrate] were determined at 7 and 14 days. NM led to significantly (p < 0.05) decreased ABL in animals subjected to ligature-induced periodontitis. Tryptase inhibition prevented the onset of significant ABL at 7 days of experiment (0.44 ± 0.16 and 0.60 ± 0.22, p > 0.05, NM+Ligature and Control, respectively) and significantly decreased the ABL at 14 days (0.97 ± 0.17 versus 1.82 ± 0.26, p < 0.001, NM+Ligature versus Ligature, respectively). In addition, NM significantly decreased MPO and total proteolytic activity at 14 days (p < 0.05). These data provided evidence that tryptase inhibition with NM attenuates gingival granulocyte infiltration and ABL in an experimental model of periodontitis in rats.


Sujet(s)
Guanidines/usage thérapeutique , Parodontite/prévention et contrôle , Inhibiteurs trypsiques/usage thérapeutique , Tryptases/antagonistes et inhibiteurs , Résorption alvéolaire/prévention et contrôle , Animaux , Benzamidines , Benzoylarginine nitroanilide , Mouvement cellulaire/effets des médicaments et des substances chimiques , Réactifs chromogènes , Gencive/effets des médicaments et des substances chimiques , Gencive/anatomopathologie , Gingivite/prévention et contrôle , Granulocytes/effets des médicaments et des substances chimiques , Mâle , Maladies mandibulaires/prévention et contrôle , Molaire/effets des médicaments et des substances chimiques , Peptide hydrolases/analyse , Myeloperoxidase/analyse , Répartition aléatoire , Rats , Rat Wistar , Récepteur de type PAR-2/analyse , Facteurs temps
6.
J Periodontol ; 82(5): 767-77, 2011 May.
Article de Anglais | MEDLINE | ID: mdl-21073332

RÉSUMÉ

BACKGROUND: Platelets contain an array of biologic mediators that can modulate inflammation and repair processes including proinflammatory mediators and growth factors. Previous studies have shown that periodontitis and periodontal repair are associated with platelet activation. We hypothesized that drug-induced platelet inactivation may interfere in the processes of inflammation and repair in experimental periodontitis in rats by suppressing the release of biologic mediators from platelets to the site of injury. METHODS: To measure the effects on periodontitis, ligatures were placed around first molars, and aspirin (Asp, 30 mg/kg) or clopidogrel (Clo, 75 mg/kg) was given intragastrically once daily for 15 days. Interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and thromboxane A(2) levels were measured by enzyme-linked immunosorbent assay. To evaluate the effects of antiplatelet drugs on periodontal repair, ligatures were removed after 15 days of periodontitis induction, and Asp or Clo were administered beginning the following day for 15 days. Periodontal repair was assessed by microcomputed tomography. RESULTS: On periodontitis phase, Asp and Clo significantly reduced levels of TNF-α and Il-6 (P <0.05), but only Asp decreased thromboxane A(2) (P <0.05). Asp and Clo decreased inflammatory infiltration; however, this reduction was more pronounced with Clo treatment (P <0.05). Histometric analysis showed that Asp and Clo impaired alveolar bone resorption. During the repair phase and after removal of the ligatures, microcomputed tomography analysis demonstrated that treatment with Asp and Clo did not impair alveolar bone repair. CONCLUSION: Systemic administration of Asp and Clo attenuates the inflammation associated with periodontitis without affecting the repair process when stimulus is removed.


Sujet(s)
Parodontite/étiologie , Parodonte/effets des médicaments et des substances chimiques , Antiagrégants plaquettaires/usage thérapeutique , Résorption alvéolaire/étiologie , Résorption alvéolaire/anatomopathologie , Résorption alvéolaire/prévention et contrôle , Animaux , Acide acétylsalicylique/usage thérapeutique , Plaquettes/effets des médicaments et des substances chimiques , Densité osseuse/effets des médicaments et des substances chimiques , Régénération osseuse/effets des médicaments et des substances chimiques , Clopidogrel , Médiateurs de l'inflammation/analyse , Protéines et peptides de signalisation intercellulaire/analyse , Interleukine-6/analyse , Leucocytes/effets des médicaments et des substances chimiques , Mâle , Maladies mandibulaires/étiologie , Maladies mandibulaires/anatomopathologie , Maladies mandibulaires/prévention et contrôle , Perte d'attache parodontale/étiologie , Perte d'attache parodontale/anatomopathologie , Perte d'attache parodontale/prévention et contrôle , Parodontite/anatomopathologie , Parodontite/prévention et contrôle , Parodonte/anatomopathologie , Activation plaquettaire/effets des médicaments et des substances chimiques , Répartition aléatoire , Rats , Rat Sprague-Dawley , Thromboxane A2/analyse , Ticlopidine/analogues et dérivés , Ticlopidine/usage thérapeutique , Facteurs temps , Facteur de nécrose tumorale alpha/effets des médicaments et des substances chimiques , Cicatrisation de plaie/effets des médicaments et des substances chimiques , Microtomographie aux rayons X
7.
Calcif Tissue Int ; 87(3): 236-45, 2010 Sep.
Article de Anglais | MEDLINE | ID: mdl-20526589

RÉSUMÉ

Bone loss associated with cyclosporin A (CsA) therapy can result in serious morbidity to patients. Intermittent administration of 1,25 Vitamin D and calcitonin reduces osteopenia in a murine model of postmenopausal osteoporosis. The purpose of this study was to evaluate the effects of this therapeutic approach on CsA-induced alveolar bone loss in rats. Forty male Wistar rats were allocated to four experimental groups according to the treatment received during 8 weeks: (1) CsA (10 mg/kg/day, s.c.); (2) 1,25 Vitamin D (2 microg/kg, p.o.; in weeks 1, 3, 5, and 7) plus calcitonin (2 microg/kg, i.p.; in weeks 2, 4, 6, and 8); (3) CsA concurrently with intermittent 1,25 Vitamin D and calcitonin administration; and (4) the control treatment group (vehicle). At the end of the 8-week treatment period, serum concentrations of bone-specific alkaline phosphatase, tartrate-resistant acid phosphatase (TRAP-5b), osteocalcin, interleukin (IL)-1 beta, IL-6, and tumor necrosis factor alpha (TNF-alpha) were measured and an analysis of bone volume, bone surface, number of osteoblasts, and osteoclasts was performed. CsA administration resulted in significant alveolar bone resorption, as assessed by a lower bone volume and an increased number of osteoclasts, and increased serum bone-specific alkaline phosphatase, TRAP-5b, IL-1 beta, IL-6, and TNF-alpha concentrations. The intermittent administration of calcitriol and calcitonin prevented the CsA-induced osteopenic changes and the increased serum concentrations of TRAP-5b and inflammatory cytokines. Intermittent calcitriol/calcitonin therapy prevents CsA-induced alveolar bone loss in rats and normalizes the production of associated inflammatory mediators.


Sujet(s)
Résorption alvéolaire/prévention et contrôle , Agents de maintien de la densité osseuse/usage thérapeutique , Calcitonine/usage thérapeutique , Calcitriol/usage thérapeutique , Maladies mandibulaires/prévention et contrôle , Acid phosphatase/sang , Administration par voie orale , Résorption alvéolaire/sang , Résorption alvéolaire/induit chimiquement , Animaux , Agents de maintien de la densité osseuse/administration et posologie , Calcitonine/administration et posologie , Calcitriol/administration et posologie , Numération cellulaire , Ciclosporine/effets indésirables , Calendrier d'administration des médicaments , Interleukines/sang , Isoenzymes/sang , Mâle , Maladies mandibulaires/induit chimiquement , Ostéoclastes/cytologie , Rats , Rat Wistar , Tartrate-resistant acid phosphatase , Facteur de nécrose tumorale alpha/sang
8.
J Periodontal Res ; 40(3): 208-11, 2005 Jun.
Article de Anglais | MEDLINE | ID: mdl-15853965

RÉSUMÉ

BACKGROUND: The purpose of the present study was to evaluate the effect of a potent selective cyclooxygenase-2 (COX-2) inhibitor, etoricoxib, on the prevention of alveolar bone loss in experimental periodontitis induced in rats. METHODS: Ninety Wistar rats were separated into three experimental groups. Cotton ligatures were placed at the gingival margin level of lower right first molars. The rats were randomly assigned to one of the following groups: control received a daily oral dose of 1 ml/kg of saline solution; Eto1 received 6 mg/kg of etoricoxib; Eto2 received 12 mg/kg of etoricoxib. Serum levels of etoricoxib and white blood cells were determined. Standardized digital radiographs were taken after death at 3, 5, 10, 18 and 30 days to measure the amount of bone loss at the mesial root surface of the first molar tooth in each rat. RESULTS: One-way analysis of variance (anova) indicated that groups treated with both doses of etoricoxib had significantly (p < 0.05) less alveolar bone loss when compared to controls. Furthermore, etoricoxib treatment significantly inhibited the leukocytosis observed 3 days after the induction of periodontitis. CONCLUSION: These data provide evidence that systemic therapy with etoricoxib can retard alveolar bone loss in a ligature-induced periodontitis model in rats.


Sujet(s)
Résorption alvéolaire/prévention et contrôle , Inhibiteurs des cyclooxygénases/sang , Parodontite/traitement médicamenteux , Pyridines/sang , Sulfones/sang , Animaux , Évaluation préclinique de médicament , Étoricoxib , Hyperleucocytose/traitement médicamenteux , Lymphocytes/effets des médicaments et des substances chimiques , Mâle , Maladies mandibulaires/prévention et contrôle , Répartition aléatoire , Rats , Rat Wistar
9.
Rev. méd. Maule ; 20(1): 15-7, jun. 2001. tab
Article de Espagnol | LILACS | ID: lil-296054

RÉSUMÉ

Considerando la alta prevalencia de patologías bucodentarias en niños chilenos (67 por ciento tiene caries y 32 por ciento sufre de anomalías del desarrollo dentomaxilar) se insiste en las medidas de prevención como lo más efectivo y dentro de ellas se destaca la lactancia materna. Se estudiaron a 128 preescolares asistentes a un jardín infantil de la ciudad de Curicó- Chile, realizándose examen bucodentario y encuesta a los padres sobre hábitos de succión perniciosos y antecedentes de alimentación con lactancia materna exclusiva. El análisis de los resultados mostró que los niños que recibieron lactancia materna tienen menos riesgo de adquirir malos hábitos de succión, que los niños alimentados sin lactancia materna. Succión digital la presentó el 5,9 por ciento de los niños que recibió lactancia materna, en cambio se presentó en el 14 por ciento de los que no recibieron lactancia materna. Respecto al uso de chupete de entretención lo usó el 32 por ciento de los niños que recibieron lactancia materna, a diferencia del 51 por ciento en los niños que no la recibieron. Los defectos de oclusión se presentaron con mayor frecuencia entre los niños que no recibieron lactancia materna, 33 por ciento de ellos, a diferencia de los niños con lactancia materna en los que solo se presenta en el 11 por ciento de ellos. También se observa una clara asociación entre los malos hábitos de succión (succión digital y succión de chupete) y los defectos de oclusión. Se concluye que la lactancia materna protege a los niños de defectos de mala oclusión, probablemente por evitar los malos hábitos de succión y permitir un adecuado desarrollo neuro-músculo-esquelético del macizo craneofacial. Por lo que se recomienda fomentar la lactancia materna


Sujet(s)
Humains , Femelle , Mâle , Enfant d'âge préscolaire , Allaitement naturel , Soutien nutritionnel/effets indésirables , Malocclusion dentaire/étiologie , Maladies mandibulaires/prévention et contrôle , Développement maxillofacial , Soutien nutritionnel/instrumentation , Malocclusion dentaire/prévention et contrôle
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE